Margherita Fogliano
Precision genome editing holds immense promise for the treatment of genetic disorders, but efficient in vivo delivery of CRISPR-Cas9 components remains a formidable challenge. This article explores the development and application of targeted nanoparticles as a delivery platform for the CRISPR-Cas9 system. We discuss the design, optimization, and in vivo testing of nanoparticles tailored to specific cell types and tissues. The integration of nanotechnology and genome editing not only enhances the precision and efficiency of genome modifications but also paves the way for potential therapeutic breakthroughs.
Partagez cet article
English 
Spanish 
Chinese 
Russian 
German 
Japanese 
Portuguese 
Hindi 